Skip to content

2 altcoins to turn $100 into $10,000

2 altcoins to turn $100 into $10,000
Paul L.

The ongoing cryptocurrency bull run has shifted attention to the start of altcoin season, with several assets showing strong potential.

To this end, Finbold has identified two altcoins worth buying now for $100 each, with the potential to turn into $10,000.

Kaspa (KAS)

Kaspa (KAS) remains a unique investment opportunity thanks to its blockDAG architecture, designed to process transactions more quickly and efficiently. At press time, KAS was trading at $0.089, with the asset facing major resistance between $0.10 and $0.11.

KAS one-week price chart. Source: Finbold

In terms of growth potential, Kaspa is gaining momentum ahead of its upcoming smart contract debut set for August 31, a milestone that could drive adoption into new areas such as DeFi and real-world applications. 

This development could propel KAS into the spotlight and allow it to compete with established players like Ethereum and Solana, with the current bull cycle serving as a key catalyst for further growth.

Aptos (APT) 

Aptos (APT), on the other hand, is carving out a space in the competitive smart contract landscape. 

At the time of reporting, Aptos was trading around $4.68, though the short-term remains weighed down by bearish sentiment in line with the broader market.

In this case, analysts are watching the $4.65 support level closely, with a breakout likely if Aptos clears resistance in the $4.85 to $5 range.

APT one-week price chart. Source: Finbold

Despite recent token unlocks that introduced new supply, the price has shown resilience, reflecting steady demand. The network continues to expand its ecosystem through DeFi integrations, hackathons, and real-world asset experiments.

If these fundamentals prove strong enough, both assets could emerge as key players in the altcoin season. While market volatility remains a risk, Kaspa and Aptos stand out as ideal bets in the race to turn $100 into $10,000.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Latest posts

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Finbold AI Agent

How AI Price Predictions Work

We use cutting-edge AI models to forecast future prices for stocks and crypto.

Trade, Swap & Stake Crypto on Uphold

Buy, sell, and swap crypto. Stake crypto, earn rewards and securely manage 300+ assets—all in one trusted platform. Terms apply. Capital at risk.

Get Started

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.